While information on the association of tau PET burden with CSF tau markers in DS is scarce, and more research is needed to understand the temporal relationship between these biomarker modalities in that population, studies in euploid adults with and without cognitive impairment have found positive correlations between CSF tau measures and PET tau burden especially in the symptomatic and amyloid-positive individuals (Janelidze et al., 2020; Gordon et al., 2016). The gene discussed is MAPT; the disease is Cognitive impairment.